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Objective: In the present protocol, employability of polymethacrylate polymer Eudragit RS100 for development of microparticles of water-soluble 
drug with desired values of response variables was investigated by central composite optimization design through the application of Design 
Expert®
Methods: The microparticles were developed by emulsion solvent evaporation process employing Eudragit RS100. Two effective independent 
variables drug: polymer ratio and stirring speed were selected to assess performance prospective of Eudragit on mean particle size, entrapment 
efficiency, percent yield and drug release in 12 h of microparticles. Thirteen batches generated by the software were prepared and subjected to 
different characterization test parameters obligatory for the evaluation of formulation. Validation of optimization model and Statistical 
interpretation of results was done using Analysis of Variance (ANOVA). 
 software (Series DX10).  
Results: ANOVA indicated that the independent variables had a significant effect on response variables. Optimized formulation demonstrated close 
agreement amongst experimental and predicted responses with high desirability factor. In vitro drug liberation study for optimized formulation 
proposed a sustained release of drug from microparticles.  
Conclusion: In conclusion, the optimization technique was imperative in indicating the efficient applicability of Eudragit RS100 polymer in 
controlling the drug release of hydrophilic drugs. 
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With the progressive research in formulation development for 
designing an optimum formulation with desired performance 
characteristics, several Statistical experimental designs such as 
factorial design, response surface methodology have emerged as 
powerful and systematic tools in multiple factor optimizations in 
fewer experimental trials [1-4]. Therefore, quality by design in this 
research protocol has been built-in by using response surface 
methodology by applying the most popular design of experiment, 
Central Composite Design (CCD); that describes optimal liaison 
among the process variables and responses for preparation of 
dosage form with desired performance characteristics [5-8].  
Losartan Potassium is an angiotensin receptor blocker recommended as 
the first-line drug for the management of blood pressure (BP). The 
marketed immediate release dosage form of the drug exhibits low oral 
bioavailability owing to narrow therapeutic index and short half-life. 
Thus, to overcome shortcomings of the currently available formulations 
and control the BP with once a day therapy; the rationale of the research 
protocol undertaken encompasses the application of computer-aided 
technology to investigate the employability of polymethacrylate polymer 
Eudragit RS100 for controlling the drug release of hydrophilic drug, 
maximizing the percent yield, entrapment efficiency and hence efficacy 
of drug. Optimization technique has not been yet applied to investigate 
the study undertaken using low permeability polymer for a hydrophilic 
drug Losartan Potassium, the first choice drug for dealing complications 
associated with hypertension along with lowering of blood pressure. 
Eudragit RS100 is being increasingly employed for the development of 
oral sustained release microspheres. It is low permeability neutral It is 
low permeability neutral polymer that is insoluble in water and digestive 
juices but swells due to the presence of quaternary ammonium groups; 
thus, releases the drug by diffusion [9, 10]. The aim of the study was to 
explore the applicability of polymethacrylate polymer Eudragit RS100 
for development of microparticles of water-soluble drug with desired 
values of response variables by central composite optimization design 
through the application of Design Expert® software. 
MATERIALS AND METHODS 
Materials 
Losartan potassium was obtained as a gratis sample from Theon 
Pharmaceuticals Pvt. Ltd., Baddi. Eudragit RS 100 was procured from 
Theon Pharmaceuticals Pvt. Ltd., Baddi. Isopropyl alcohol, Light liquid 
paraffin, n-hexane, methanol, dichloromethane were obtained from Loba 
Chemicals Private Limited. Talc, Span 80, potassium dihydrogen 
orthophosphate, sodium hydroxide and concentrated hydrochloric acid 
were purchased from SD Fine Chemicals.  
Methods 
Design of experiment 
Central composite design (CCD) was employed using Design Expert® 
software (Trial Version DX10, Stat-Ease Inc., Minneapolis, USA) to 
prepare microspheres of Losartan potassium by emulsion solvent 
evaporation method using Eudragit RS 100. To optimize the 
formulation variables, factors selected for the study were drug: 
polymer ratio (A) and stirring speed (B) taken at five different levels 
viz.–alpha, low, center point, high-level and+alpha level as shown in 
table 1. The response or dependent variables studied were mean 
particle size (Y1), drug entrapment efficiency (Y2), percent yield 
(Y3) and drug release at 12th
Statistical analysis was done using the software to generate linear, 
quadratic, cubic, Cross-product (2FI) models for the responses. The 
statistical interpretation of the results by Analysis of Variance (ANOVA) 
was done to establish which factors have a statistically significant effect 
on the response parameters and to ascertain validation of polynomial 
equations. The suitability of the model was resolute by the comparisons 
between the statistical parameters and the best fit model (suggested) 
 hour (Y4). 
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was chosen based on reasonable concurrence between multiple 
correlation coefficients; adjusted R2 and predicted R2 
  
(within 0.2 of each 
other), higher values of these coefficients (greater than 80%), model p-
value (should be less than 0.05) and Lack-of fit measures. Contour and 
response plots resulting from the equations were developed utilizing the 
software. Numerical optimization and checkpoint formulations (CPF) 
method was applied to arrive at the optimized formulation through the 
desirability function approach. 
Table 1: Central composite design (CCD) matrix, actual or coded values 
S. No. Independent variables Coded and Actual levels 
(-1.41421) 
Alpha level 






1. Drug: Polymer ratio (w/w), A 1.58 1:2 1:3 1:4 4.41 
2. Stirring Speed (rpm), B 717 800 1000 1200 1282 
 
Preparation of microspheres 
The microspheres of Losartan potassium were prepared by varying 
the drug and polymer ratio and co-dissolving them into a mixture of 
methanol-acetone (1:1 v/v) with continuous stirring using Remi’s 
mechanical stirrer (Model: RQ-121/D). The resultant dispersion was 
slowly introduced into light liquid paraffin containing span 80 (final 
concentration 1% w/w) as an emulsifying agent). The drug: polymer 
ratio and stirring speed were varied as per CCD experimental design. 
Light liquid paraffin was decanted and the microparticles were 
recovered by filtration followed by washings with n-hexane to remove 
paraffin. The resulting microparticles were dried at room temperature 
for 24 h and evaluated for various in vitro parameters [11-14].  
Optimization and validation model 
Diverse batches of losartan potassium loaded eudragit 
microparticles were prepared as per the CCD and a total of 13 runs 
were presented by the Design Expert®
  
 software. The design matrix 
is shown in table 2. 
Table 2: Central composite design matrix, the observed responses 
Runs Independent variables 
Drug: polymer ratio (A), w/w Stirring speed (B), rpm 
1.  1 -1 
2.  0 0 
3.  -1 1 
4.  1 1 
5.  0 0 
6.  -1 -1 
7.  0 -1.41421 
8.  -1.41421 0 
9.  1.41421 0 
10.  0 0 
11.  0 0 
12.  0 0 
13.  0 1.41421 
 
The response (Yi) in each testing run was calculated by carrying out 
a regression analysis to develop equations for (Y1-Y4). 
Yi = β0+β1A+β2B+β3AB+β4A2+β5B2




is the intercept of the polynomial equation, 
1-5 
AB are the coefficients corresponding interaction and 
represents an estimated regression coefficient for factor A and B 
A2 and B2
Evaluation of microparticles 
represent the quadratic effects [8, 15]. 
Microparticles were evaluated for micromeritic properties by 
measuring the angle of repose, bulk density, tapped density, Carr’s 
index and Hausner ratio using standard reported procedures. The 
average particle size of microspheres was analyzed by simple optical 
microscopy method using the ocular lens and stage micrometer. 
Approximately 300 microspheres were counted and the average 
equivalent spherical diameter was measured [16-18]. The drug 
entrapment efficiency was determined by taking accurately weighed 
microspheres equivalent to 25 mg of losartan potassium and 
crushed to obtain a fine powder. The powder was dissolved in 100 
ml of phosphate buffer pH 6.8 in a conical flask. The solution 
obtained was filtered, suitably diluted and analyzed 
spectrophotometrically using Ultraviolet-Visible (UV-VIS) double 
beam spectrophotometer at 235 nm. All the readings were taken in 
triplicate. Drug content was determined by the following formula:  
Drug entrapment efficiency (%) = Conc.of drug present in microspheres
Amount of Drug initially Taken
 X 100 Eq. (2) 
The microspheres obtained were weighed accurately and the 
percentage yield was calculated as the weight of losartan potassium 
microspheres recovered from each batch in relation to the sum of 
starting material [19-21]. 
Yield (%) = Actual weight of the microspheres obtained
Total weight of the excipients and drug
 X 100 Eq. (3) 
On the basis of the optimization and validation model, the optimized 
formulation was selected for further analysis. Fourier Transform 
Infra-Red (FTIR) spectra of pure drug and optimized formulation 
were recorded using ATR-FTIR spectrophotometer to investigate 
any possible interaction between drug-loaded microspheres. The 
morphology of optimized formulation of microspheres was 
examined by Scanning electron microscope analysis using SEM; Jeol 
JSM-6400, Japan. To analyze the existence condition of Losartan 
Potassium (LP) in the microspheres, Differential Scanning 
Calorimetry (DSC) of the LP microspheres was carried out. 
In vitro drug release study was carried out in simulated 
physiological pH 6.8 using USP Type I dissolution apparatus at 
37±0.5 °C to calculate the amount of drug released from 
microspheres. The assembly was operated at 100 rpm under sink 
conditions thereby maintaining the constant dissolution volume of 
900 ml. The sample was withdrawn at suitable time intervals and 
replaced with a fresh equal volume of dissolution medium. The 
samples withdrawn were analyzed using double beam UV-VIS 
spectrophotometer at 235 nm to determine the percent drug 
released. The dissolution data so obtained were fitted to various 
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drug-release kinetic models such as Zero order, First order, Higuchi 
and Korsmeyer Peppas model. The release kinetics was assessed by 
comparing the values of the regression coefficient (r2
RESULTS  
) [22, 23].  The investigated response variables for the conducted experimental trials are shown in table 3. 
  
Table 3: Central composite design matrix, the observed responses 
Runs Independent variables Dependent variables 
Drug: polymer 
ratio (A), w/w 
Stirring speed 
(B), rpm 






Drug rel at 12thh 
(Y4), (%)* 
1.  1 -1 169.2±1.23 71.37±1.23 65.49±0.74 67.96±2.62 
2.  0 0 121.26±2.38 79.73±1.09 76.49±1.73 76.55±1.29 
3.  -1 1 102.28±2.03 70.39±1.54 75.15±2.47 75.94±0.47 
4.  1 1 140.66±0.86 74.18±1.25 74.59±1.74 74.69±1.20 
5.  0 0 120.48±1.01 78.44±0.89 76.68±1.26 75.35±1.40 
6.  -1 -1 119.69±1.03 69.3±2.26 77.98±1.74 76.68±0.82 
7.  0 -1.41421 145.69±0.36 73.05±0.63 70.26±1.23 64.19±2.95 
8.  -1.41421 0 100.96±1.47 67.95±1.78 76.85±2.05 77.19±2.40 
9.  1.41421 0 163.79±1.59 73.67±1.78 67.95±0.86 73.89±1.23 
10.  0 0 120.03±1.15 79.1±0.83 67.45±0.55 80.64±2.29 
11.  0 0 119.49±1.33 80.74±1.02 69.64±1.32 66.55±3.54 
12.  0 0 120.55±0.38 78.88±1.90 65.29±1.96 80.95±2.78 
13.  0 1.41421 113.68±2.59 75.96±2.44 62.56±1.08 79.25±1.40 
*
 
Statistical data analysis and model validation 
All values are expressed as mean±SD, n = 6 (for standard deviation) 
Linear, quadratic, cubic, Cross-product (2FI) models were generated by 
the software for the responses. The ANOVA for the regression model 
demonstrated that the quadratic model was greatly significant as 
indicated by the p-value, <0.0001 and R2
 
near to 1. The equations 
generated (as shown in table 4) were used to quantify the response data. 
Positive sign of coefficient indicated synergistic effect (increase in 
response) while negative sign indicated antagonistic effect (decrease in 
response values) as the factor was changed from low to a high level [24]. 
Table 4: Equations for quadratic model 
Response Intercept  A  B  AB  A^2  B^2 
Mean Particle Size (Y1) 120.362 22.0931 -11.4024 -2.7825 6.48837 5.14337 
p-value  <0.0001 <0.0001 0.0019 <0.0001 <0.0001 
Entrapment Efficiency (Y2) 79.378 1.74366 1.00192 0.43 -4.62087 -2.77337 
p-value  0.0020 0.0286 0.4318 <0.0001 0.0002 
Percent Yield (Y3)  76.63 1.13 1.96 0.50 -6.14 -2.96 
p-value  0.0322 0.0024 0.4338 <0.0001 0.0003 
Drug rel at 12th 76.342  h (Y4) -6.04726 -0.0735786 -0.275 -2.056 -0.771 
p-value  <0.0001 0.8618 0.6478 0.0022 0.1210 
 
The values for mean particle size showed a broad variation ranging 
from 100.96±1.47 to 169.20±1.23 µm. The data as well as model 
evidently signified that the independent variables drug: polymer 
ratio (A) and stirring speed (B), their interaction term (AB) and the 
quadratic terms (A2and B2
Validation by checkpoint formulation (CPF) and Numerical 
optimization 
) showed a significant effect on particle 
size (Y1), p<0.0001. Expanding the drug: polymer proportion 
brought about the mean microparticle size to move towards a higher 
value, as indicated by the positive coefficients of A. On the other 
hand, mean particle size decreased with increase in stirring speed as 
indicated by the negative coefficients of B, p<0.0001. The values of 
drug entrapment efficiency (Y2) for the various experimental runs 
ranged between 67.95±1.78 to 80.74±1.02 %. With the increase in 
independent variables, the entrapment efficiency increased up to the 
middle level than it started decreasing on further increase in A and 
B. The yield values for all the runs demonstrated wide difference 
going from a lowest of 62.56±1.08 to a highest of 77.98±1.74 %. 
In-vitro drug release data for all the experimental runs ranged 
between 64.19±2.62 to 80.95±2.78 %.  
To approve the model equations resulting from regression analysis, 
Numerical optimization method was applied to arrive at the optimized 
formulation through the desirability function approach. The 
accompanying blend of independent variables (CPF) was recommended 
by the software with the desirability function of 0.840. Table 5 shows the 
predicted and experimental values of both the responses and the value 
of residuals obtained with error value less than 1. 
  
Table 5: Validation of model with CPF and numerical optimization 
S. No. Composition Response variables Experimental values Predicted values Residuals 
A (w/w) B (rpm) 
CPF  2.75 1065 Mean particle Size (Y1), (µm) 
Entrapment efficiency (Y2), (%) 
Percent Yield (Y3), (%) 
Drug Rel at 12th
113.17±0.86 












n = 6 (for standard deviation), to graphically envision the effect of formulation/operation variables on the output variables, Contour and Response 
surface plot were constructed using the software as shown in fig. 1. 
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Fig. 1: 2D contour and 3D response surface for optimized formulation 
 
Evaluation of microparticles 
Formulations of microspheres indicated good flow properties as was 
observed from the various characteristics evaluation parameters. The 
values for the angle of repose lied between 26.78°±0.64 to 34.57 
°±0.36, Carr’s compressibility index for various formulations was in 
range 12.03 to 23.08 % while the data obtained for Hausners ratio 
ranged between 1.14 to 1.30. The results indicated good to fair flow 
properties of microspheres. FTIR studies of losartan potassium, (A) 
and optimized formulation (B) were compared for any kind of 
unwanted significant interaction. FTIR spectra did not show any 
significant changes in the principal peaks of pure drug indicating an 
absence of chemical interaction between the drug and polymer (fig. 2). 
The comparison of spectral assignment for pure drug and mixture has 
been shown in table 6. The shape of optimized formulation was 
examined by Scanning electron microscope (SEM) analysis. The study 
(fig. 3) revealed that the discrete, uniformly shaped spherical 
microspheres were obtained. The DSC trace of LP showed a sharp 
thermographic peak at 274.8 and a broad endothermic peak at the 
same temperature as shown in fig. 4 and 5 respectively. 
 
 
Fig. 2: FTIR spectra of (A) Losartan potassium and (B) optimized formulation 
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Table 6: Spectral assignment of losartan potassium and optimized formulation 
S. No. Wave number (cm-1 Wave number (cm) losartan potassium -1 Vibration mode ) optimized formulation 
1 3000 2987.98 C-H stretching 
2 2960 2956.14 Distinct band sym CH3
3 
 group 
1458 1459.60 Stretching aromatic C-C ring  
4 3189.8 3197.48  Stretching O-H  
5 841.5 763.61 Stretching C-Cl 
 
 
Fig. 3: Scanning electron microscope analysis of optimized microsphere formulation 
 
 
Fig. 4: Differential scanning calorimetric analysis of pure drug (Losartan Potassium) 
 
 
Fig. 5: Differential scanning calorimetric analysis of optimized formulation 
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The dissolution data so obtained was then fitted to various drug-
release kinetic models. The release mechanism was assessed by 
comparing the values of the regression coefficient (r2) as shown in 
table 7. The value of the regression coefficient was found to be higher 
for Korsmeyer–Peppas model i.e. r2
 
= 0.976. The various dissolution 
models for optimized formulation have been shown in fig. 6. 
Table 7: Regression data for various dissolution kinetic models 
S. No. Parameter Dissolution kinetic model 
Zero order First order Higuchi model Koresmeyer peppas model 
1 Regression equation y = 7.770x-2.737 y =-0.065x+2.077 y = 27.98x-19.78 y = 1.231x+0.660 
2 Correlation coefficient (r2 0.959 ) 0.944 0.878 0.976 
 
 
Fig. 6: Dissolution models for optimized formulation (a) Zero order, (b) First order, (c) Higuchi model and (d) Koresmeyer peppas model 
 
DISCUSSION 
Microspheres of losartan potassium were prepared using a mixed 
solvent system and light liquid paraffin as the dispersed phase and 
continuous phase respectively to facilitate the formation of 
microparticles by emulsion solvent evaporation method with Eudragit 
RS100. Judicial selection of solvent system was done based on their 
dielectric constants. The solvents having dielectric constant above 10 
and below 40 reflect poor miscibility in light liquid paraffin; therefore, 
paraffin was preferred as a continuous phase in which both losartan 
potassium and Eudragit RS100 are scantily soluble [25]. Span 80 was 
supplemented as an emulsifier to prevent coalescence of droplets during 
solvent evaporation. Emulsion solvent evaporation was found reliable 
for preparation of microparticles of losartan potassium.  
The data generated by statistical experimental design clearly 
signified that the independent variables (A) and (B), their 
interaction term (AB) and the quadratic terms (A2and B2
On the other hand, in case of entrapment efficiency (Y2), it was 
experiential that with the increase in independent variables, the 
former increased up to the middle level than it started decreasing on 
further increase in A owing to the fact that an increase in polymer 
concentration in a fixed volume of organic solvent resulted in 
augmenting the entrapment efficiency.  
) showed a 
significant effect on response variables (Y1-Y4); (p<0.0001). 
Initially, expanding the drug: polymer proportion brought about the 
mean microparticle size to move towards a higher value, as 
indicated by the positive coefficients of A, which can be attributed to 
the fact that higher polymer concentration produced more viscous 
dispersion and therefore, shearing effect was less at impeded 
circulation that formed larger droplets [17, 18]. Microscopic analysis 
of formulations revealed that stirring speed plays an important role 
in determining the size and shape of microparticles. Mean particle 
size decreased with increase in stirring speed producing uniform 
spherical microparticles.  
In case of percent yield (Y3), it was observed that as the drug: 
polymer ratio was increased, the total material in the dispersed 
phase increased. Finer particles formed during the preparation of 
microparticles tend to coalesce to give bigger particles with better 
percent yield. The model applied for drug release at 12th
The ANOVA for the regression model demonstrated that the 
quadratic model was highly significant as indicated by the p-value. 
The reasonably lower values of residual between predicted and 
observed experimental values for all the four response variables 
indicated a pragmatic agreement between the predicted and trial 
values were observed. Hence, the mathematical model was well 
fitted. Numerical optimization technique using the desirability 
function approaching 1 for obtaining optimized formulation 
indicated desirable range for independent variables A and B to get 
the optimum response for further investigation. SEM study revealed 
that the discrete, uniformly shaped spherical microspheres were 
 hour (Y4) 
showed that as the drug: polymer ratio was varied towards higher 
side, the drug release retarded from the formulations as diffusional 
path length for drug release increased while with increase in stirring 
speed the interfacial area per unit volume increased, so, the drug 
release also increased [8, 26-28]. 
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obtained. DSC results indicated that there is no change of LP in the 
pure state, formulation of microspheres. LP existed in an amorphous 
as a molecular dispersion in the polymeric matrix. In vitro drug 
liberation study for optimized formulation proposed a sustained 
release of drug from microparticles indicating the efficient 
applicability of Eudragit RS100 polymer in controlling the drug 
release of hydrophilic drugs. 
CONCLUSION 
In the present research, the statistical experimental design approach 
was undertaken for preparing microparticles of losartan potassium 
by modified solvent evaporation process using Eudragit RS100 as 
polymer. From the results of various in vitro evaluation parameters, 
it was concluded that optimization plays an important role in 
designing of dosage forms with desired performance characteristics.  
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